Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs

Title:Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs

Volume: 17 Issue: 11

Author(s): Karina Vázquez, Margot Paulino, Cristian O. Salas, Juan J. Zarate-Ramos, Brenda Vera and Gildardo Rivera*

Affiliation:

• Centro de Biotecnologia Genomica, Instituto Politecnico Nacional, Boulevard del Maestro, s/n, Esquina Elías Piña, Reynosa, 88710,Mexico

Keywords: Chagas disease, trypanothione reductase, Trypanosoma cruzi, target, drugs, inhibitors.

Abstract: Background & Objective: Chagas disease or American trypanosomiasis is a major parasitic disease in Latin America with restricted available treatment: nifurtimox and benznidazole. These two drugs are ineffective in the chronic phase of the disease; therefore, there is a need for the development of new, efficient and safe drugs for the treatment of this pathology. With this goal, one of the promising targets is trypanothione reductase (TR), a key enzyme in the metabolism of Trypanosoma cruzi.

Conclusion: In this review, we analyse the importance of TR as a drug target, as well as the well-known and new inhibitors reported in the last decade as potential therapeutic agents for Chagas disease.

Cite this article as:

Vázquez Karina , Paulino Margot , Salas O. Cristian , Zarate-Ramos J. Juan, Vera Brenda and Rivera Gildardo *, Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs, Mini-Reviews in Medicinal Chemistry 2017; 17 (11) . https://dx.doi.org/10.2174/1389557517666170315145410